American Society of Clinical Oncology Educational Book · 2021 · 57 citations · 134 references
MedicineHematologyHematologic OncologyImmunotherapyMolecular OncologyBone Marrow EvaluationHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyPatient StratificationAutologous Stem Cell TherapyHigh-risk Multiple MyelomaProteasome Inhibitor TherapyProteasome InhibitorsRelapsed Disease TherapyRelapsed Multiple MyelomaRevised International Prognostic Scoring SystemTriplet Therapy Regimens
Survival in multiple myeloma has improved greatly during the past 2 decades, but this change has primarily benefited patients who have standard-risk disease. Patients with high-risk disease remain a challenge to diagnose and treat. To improve their clinical outcomes, it is imperative to develop tools to readily identify them and to provide them with the most effective available treatments. The most widely used stratification system, the revised International Staging System, incorporates serum β-2 microglobulin, albumin, lactate dehydrogenase, and high-risk chromosomal abnormalities [del(17p), t(4;14), and t(14;16)]. Recent updates have included mutational status and chromosome 1q abnormalities. Plasma cell leukemia, extramedullary disease, circulating plasma cells, renal failure, and frailty are also associated with poor outcome. The treatment approach for a newly diagnosed patient with high-risk multiple myeloma should include induction therapy, autologous stem cell transplantation if appropriate, and maintenance therapy. Triplet therapy with a proteasome inhibitor, immunomodulatory drug, and steroid, with or without an anti-CD38 antibody, should be considered for induction, along with a proteasome inhibitor and/or immunomodulatory drug for maintenance. Aiming for a deep and sustained response is important. Similar principles apply at relapse, with close monitoring of response, especially extramedullary disease and active management of side effects, so that patients can continue therapy and benefit from treatment. Immune-based therapies, including autologous CAR T-cell-based therapies and bispecific antibodies, show promising activity in relapsed disease and are being actively explored in earlier disease settings. As the prognosis for high-risk disease remains poor, the future goal for this patient group is to develop specific clinical trials to explore novel approaches and therapies efficiently.
134
International Staging System for Multiple Myeloma
Philip R. Greipp, Jesús F. San Miguel, Brian G.M. Durie et al. · Journal of Clinical Oncology · 2005 · 2.9K citations
Medicine, Hematology, Oncology +14
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi, Larry D. Anderson, Nina Shah et al. · New England Journal of Medicine · 2021 · 2.4K citations · Full text
Medicine, Hematology, Oncology +17
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
J. A. Child, Gareth J. Morgan, Faith E. Davies et al. · New England Journal of Medicine · 2003 · 1.8K citations · Full text
Medicine, Hematology, Oncology +17
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje, Jesús G. Berdeja, Yi Lin et al. · New England Journal of Medicine · 2019 · 1.7K citations · Full text
Medicine, Immunology, Oncology +17